INTRODUCTION TO THE CROSS-SECTIONAL STUDY OF TYPE 2 DIABETES MELLITUS AND MICROVASCULAR COMPLICATIONS: A CROSS-SECTIONAL STUDY AT A TERTIARY CARE HOSPITAL
Main Article Content
Keywords
Type 2 diabetes mellitus; newly diagnosed; HbA1c; microvascular complications; diabetic retinopathy; diabetic nephropathy; diabetic neuropathy; dyslipidaemia; India
Abstract
Background: Type 2 diabetes mellitus (T2DM) is a worldwide epidemic and India has second largest burden of diabetes in the world. Microvascular complications, such as retinopathy, nephropathy and neuropathy, can occur at diagnosis and are evidence of years of unnoticed hyperglycaemia. Knowing the metabolic and microvascular burden at the first diagnosis is crucial for early targeted intervention. Methods: A cross sectional study was carried out by enrolling 300 drug naïve adults with newly diagnosed T2DM (A1C ≥ 6.5% at the time of diagnosis <6 months). Comprehensive glycaemic profiling (FPG, PPPG, HbA1c), fasting lipid profile, spot urinary albumin-creatinine ratio (ACR), fundus photography for diabetic retinopathy (DR), biothesiometry/10-g monofilament for peripheral neuropathy, and eGFR were performed. Patients were stratified by HbA1c: <8%, 8–9.9%, and ≥10%. Results: Mean HbA1c was 9.4 ± 2.1%. Dyslipidaemia was present in 71.0% (hypertriglyceridaemia 48.0%, low HDL 56.0%). Any microvascular complication was detected in 36.7%: albuminuria 22.0%, retinopathy 14.0%, peripheral neuropathy 31.3%. The prevalence of all microvascular complications rose significantly with HbA1c ≥10%. In multivariable analysis, HbA1c ≥10%, central obesity (waist ≥90 cm in men, ≥80 cm in women), and hypertriglyceridaemia were independent predictors of microvascular complications. Conclusion: A substantial proportion of newly diagnosed T2DM patients already harbour microvascular complications, underscoring the 'ticking-clock' phenomenon of pre-diagnostic hyperglycaemia. Simultaneous metabolic and microvascular evaluation at the time of diagnosis and early multifactorial intervention are essential.
References
[2] Anjana RM, Unnikrishnan R, Deepa M, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023;11(7):474-89.
[3] Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care. 1992;15(7):815-9.
[4] Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316(7134):823-8.
[5] Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-89.
[6] Rema M, Premkumar S, Anitha B, Deepa R, Pradeepa R, Mohan V. Prevalence of diabetic retinopathy in urban India: the Chennai Urban Rural Epidemiology Study (CURES) eye study, I. Invest Ophthalmol Vis Sci. 2005;46(7):2328-33.
[7] Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009;5(3):150-9.
[8] Misra A, Chowbey P, Makkar BM, et al. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India. 2009;57:163-70.
[9] American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes — 2024. Diabetes Care. 2024;47(Suppl 1):S1-321.
[10] Lyons TJ, Basu A. Biomarkers in diabetes: hemoglobin A1c, vascular and tissue markers. Transl Res. 2012;159(4):303-12.
[11] Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840-6.
[12] Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28(4):956-62.
[13] Pendsey SP. Understanding diabetic foot. Int J Diabetes Dev Ctries. 2010;30(2):75-9.
[14] Indian Council of Medical Research. ICMR guidelines for management of type 2 diabetes 2018. New Delhi: ICMR; 2018.

